{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:15:15Z","timestamp":1791494115318,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40265-025-02229-2","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:33:38Z","timestamp":1756571618000},"page":"1429-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights \u2013 A Systematic Review"],"prefix":"10.1007","volume":"85","author":[{"given":"Arrigo F. G.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashot","family":"Avagimyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Nardoianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"10","key":"2229_CR1","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/imj.16189","volume":"53","author":"RJ Chan","year":"2023","unstructured":"Chan RJ, Helmeczi W, Hiremath SS. Revisiting resistant hypertension: a comprehensive review. Intern Med J. 2023;53(10):1739\u201351. https:\/\/doi.org\/10.1111\/imj.16189.","journal-title":"Intern Med J"},{"issue":"2","key":"2229_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98\u2013105. https:\/\/doi.org\/10.1136\/heartjnl-2018-313599.","journal-title":"Heart"},{"issue":"6","key":"2229_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1751-7176.2011.00437.x","volume":"13","author":"MR Weir","year":"2011","unstructured":"Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ 3rd, Graff A, Shojaee A, Waverczak WF, Qian C, Jones CJ, Neutel JM. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil \u00b1 hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011;13(6):404\u201312. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00437.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/VHRM.S25743","volume":"7","author":"D Duprez","year":"2011","unstructured":"Duprez D, Ferdinand K, Purkayastha D, Samuel R, Wright R. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Vasc Health Risk Manag. 2011;7:701\u20138. https:\/\/doi.org\/10.2147\/VHRM.S25743.","journal-title":"Vasc Health Risk Manag."},{"issue":"10008","key":"2229_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society\u2019s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","journal-title":"Lancet"},{"issue":"1","key":"2229_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/phar.4618","volume":"45","author":"S Mitsuboshi","year":"2025","unstructured":"Mitsuboshi S, Morizumi M, Imai S, Hori S, Kotake K. Association between mineralocorticoid receptor antagonists and kidney harm: a systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy. 2025;45(1):43\u201353. https:\/\/doi.org\/10.1002\/phar.4618.","journal-title":"Pharmacotherapy"},{"issue":"16","key":"2229_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(16): e0254. https:\/\/doi.org\/10.1097\/MD.0000000000010254.","journal-title":"Medicine (Baltimore)"},{"issue":"33","key":"2229_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"12","key":"2229_CR9","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fern\u00e1ndez-Alfonso MS, Halimi JM, J\u00e1rai Z, Jelakovi\u0107 B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"3","key":"2229_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","volume":"47","author":"EL Schiffrin","year":"2006","unstructured":"Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312\u20138. https:\/\/doi.org\/10.1161\/01.HYP.0000201443.63240.a7.","journal-title":"Hypertension"},{"key":"2229_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2229_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"15","key":"2229_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154572","volume":"13","author":"AFG Cicero","year":"2024","unstructured":"Cicero AFG, ALGhasab NS, Tocci G, Desideri G, Fiorini G, Fogacci F. Efficacy and safety of low-dose bisoprolol\/hydrochlorothiazide combination for the treatment of hypertension: a systematic review and meta-analysis. J Clin Med. 2024;13(15): 4572. https:\/\/doi.org\/10.3390\/jcm13154572.","journal-title":"J Clin Med"},{"issue":"8","key":"2229_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70000","volume":"17","author":"H Shimizu","year":"2024","unstructured":"Shimizu H, Tortorici MA, Ohta Y, Ogawa K, Rahman SMA, Fujii A, Hiraga Y, Kawai M, Sugimoto-Kawabata K, van Iersel MT, van Lier JJ, Djedjos S, Slingsby BT, Rodman DM. First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. Clin Transl Sci. 2024;17(8): e70000. https:\/\/doi.org\/10.1111\/cts.70000.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2229_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108\u201318. https:\/\/doi.org\/10.1038\/s41440-022-01070-4.","journal-title":"Hypertens Res"},{"issue":"4","key":"2229_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","volume":"13","author":"MW Freeman","year":"2024","unstructured":"Freeman MW, Halvorsen YD, Bond M, Murphy B, Isaacsohn J. Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in participants with varying degrees of renal function. Clin Pharmacol Drug Dev. 2024;13(4):410\u20138. https:\/\/doi.org\/10.1002\/cpdd.1371.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"2229_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ, BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169.","journal-title":"N Engl J Med"},{"issue":"6","key":"2229_CR18","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/dom.15518","volume":"26","author":"SR Bornstein","year":"2024","unstructured":"Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, Tuttle KR, Hadjadj S, Rossing P. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, phase I trial. Diabetes Obes Metab. 2024;26(6):2128\u201338. https:\/\/doi.org\/10.1111\/dom.15518.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2229_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000534808","volume":"55","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Rossing P, Hauske SJ, Cronin L, Hussain J, de Zeeuw D, Heerspink HJL. Methods article for a study protocol: study design and baseline characteristics for aldosterone synthase inhibition in chronic kidney disease. Am J Nephrol. 2024;55(2):262\u201372. https:\/\/doi.org\/10.1159\/000534808.","journal-title":"Am J Nephrol"},{"issue":"10424","key":"2229_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P, ASi in CKD group. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02408-X.","journal-title":"Lancet"},{"issue":"8","key":"2229_CR21","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/bcp.15713","volume":"89","author":"P Mulatero","year":"2023","unstructured":"Mulatero P, Groessl M, Vogt B, Schumacher C, Steele RE, Brooks A, Hossack S, Brunner HR. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers. Br J Clin Pharmacol. 2023;89(8):2483\u201396. https:\/\/doi.org\/10.1111\/bcp.15713.","journal-title":"Br J Clin Pharmacol"},{"key":"2229_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102576","volume":"71","author":"P Mulatero","year":"2024","unstructured":"Mulatero P, Wuerzner G, Groessl M, Sconfienza E, Damianaki A, Forestiero V, Vogt B, Brunner H, Gerlock T, Steele R, Schumacher C. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. EClinicalMedicine. 2024;71: 102576. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102576.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"2229_CR23","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, Slingsby BT, Nissen SE, Target-HTN Investigators. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial. JAMA. 2023;330(12):1140\u201350. https:\/\/doi.org\/10.1001\/jama.2023.16029.","journal-title":"JAMA"},{"issue":"18","key":"2229_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, Weir MR, Ofili EO, Mehra R, Luther JM, Cohen DL, Sarraju A, Wilkinson MJ, Flack JM, Rodman D, Nissen SE, Advance-HTN Investigators. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392(18):1813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2501440.","journal-title":"N Engl J Med"},{"issue":"3","key":"2229_CR25","doi-asserted-by":"publisher","first-page":"147032031771788","DOI":"10.1177\/1470320317717883","volume":"18","author":"J Sloan-Lancaster","year":"2017","unstructured":"Sloan-Lancaster J, Raddad E, Flynt A, Jin Y, Voelker J, Miller JW. LY3045697: results from two randomized clinical trials of a novel inhibitor of aldosterone synthase. J Renin-Angiotensin-Aldosterone Syst. 2017;18(3):1470320317717883. https:\/\/doi.org\/10.1177\/1470320317717883.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"9","key":"2229_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1751-7176.2012.00667.x","volume":"14","author":"K Andersen","year":"2012","unstructured":"Andersen K, Hartman D, Peppard T, Hermann D, Van Ess P, Lefkowitz M, Trapani A. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2012;14(9):580\u20137. https:\/\/doi.org\/10.1111\/j.1751-7176.2012.00667.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"18","key":"2229_CR27","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, M\u00e9nard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124(18):1945\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.029892.","journal-title":"Circulation"},{"issue":"8","key":"2229_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1517\/14728222.2016.1151873","volume":"20","author":"R Bernhardt","year":"2016","unstructured":"Bernhardt R. The potential of targeting CYP11B. Expert Opin Ther Targets. 2016;20(8):923\u201334. https:\/\/doi.org\/10.1517\/14728222.2016.1151873.","journal-title":"Expert Opin Ther Targets"},{"key":"2229_CR29","doi-asserted-by":"publisher","unstructured":"Antonini S, Brunetti A, Zampetti B, Boeris D, Saladino A, Cesare Cozzi R. Osilodrostat in Cushing\u2019s disease: the management of its efficacy and the pitfalls of post-surgical results. Endocrinol Diabetes Metab Case Rep. 2022; https:\/\/doi.org\/10.1530\/EDM-22-0311","DOI":"10.1530\/EDM-22-0311"},{"issue":"9","key":"2229_CR30","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","volume":"81","author":"GP Rossi","year":"2024","unstructured":"Rossi GP, Rossi FB, Guarnieri C, Rossitto G, Seccia TM. Clinical management of primary aldosteronism: an update. Hypertension. 2024;81(9):1845\u201356. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.22642.","journal-title":"Hypertension"},{"issue":"2","key":"2229_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","volume":"31","author":"G Nardoianni","year":"2024","unstructured":"Nardoianni G, Pala B, Scoccia A, Volpe M, Barbato E, Tocci G. Systematic review article: new drug strategies for treating resistant hypertension-the importance of a mechanistic, personalized approach. High Blood Press Cardiovasc Prev. 2024;31(2):99\u2013112. https:\/\/doi.org\/10.1007\/s40292-024-00634-4.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"10","key":"2229_CR32","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","volume":"31","author":"CD Schumacher","year":"2013","unstructured":"Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013;31(10):2085\u201393. https:\/\/doi.org\/10.1097\/HJH.0b013e328363570c.","journal-title":"J Hypertens"},{"issue":"5","key":"2229_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1365-2265.2007.03116.x","volume":"68","author":"EM Freel","year":"2008","unstructured":"Freel EM, Ingram M, Wallace AM, White A, Fraser R, Davies E, Connell JM. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects. Clin Endocrinol (Oxf). 2008;68(5):700\u20136. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03116.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2229_CR34","doi-asserted-by":"publisher","unstructured":"Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021;374:n1380. https:\/\/doi.org\/10.1136\/bmj.n1380. Erratum in: BMJ. 2021;374:n1936 https:\/\/doi.org\/10.1136\/bmj.n1936","DOI":"10.1136\/bmj.n1380"},{"issue":"3","key":"2229_CR35","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","volume":"110","author":"M Azizi","year":"2025","unstructured":"Azizi M, Riancho J, Amar L. Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases. J Clin Endocrinol Metab. 2025;110(3):e557\u201365. https:\/\/doi.org\/10.1210\/clinem\/dgae823.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2229_CR36","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","volume":"82","author":"L Marzano","year":"2025","unstructured":"Marzano L, Merlo M, Martinelli N, Pizzolo F, Friso S. Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review. Hypertension. 2025;82(4):e47\u201356. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23962.","journal-title":"Hypertension"},{"issue":"6","key":"2229_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/ehjcvp\/pvae049","volume":"10","author":"F G\u00f6tzinger","year":"2024","unstructured":"G\u00f6tzinger F, Kunz M, Lauder L, B\u00f6hm M, Mahfoud F. New ways of mitigating aldosterone in cardiorenal disease. Eur Heart J Cardiovasc Pharmacother. 2024;10(6):557\u201365. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae049.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"Suppl A","key":"2229_CR38","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1093\/eurheartj\/suy028","volume":"21","author":"J Tromp","year":"2019","unstructured":"Tromp J, van der Meer P. Hyperkalaemia: aetiology, epidemiology, and clinical significance. Eur Heart J Suppl. 2019;21(Suppl A):A6\u201311. https:\/\/doi.org\/10.1093\/eurheartj\/suy028.","journal-title":"Eur Heart J Suppl"},{"issue":"27","key":"2229_CR39","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","volume":"46","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Pitt B, Ferreira JP, Rossignol P, Girerd N, Zannad F. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease. Eur Heart J. 2025;46(27):2618\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf225.","journal-title":"Eur Heart J"},{"issue":"7","key":"2229_CR40","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1007\/s00210-025-03838-0","volume":"398","author":"F Schulze","year":"2025","unstructured":"Schulze F, Schaible J, Goettel M, Tanaka Y, Hohl K, Schultz A, Jang IJ. Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(7):9083\u201398. https:\/\/doi.org\/10.1007\/s00210-025-03838-0.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"2229_CR41","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","volume":"40","author":"PK Judge","year":"2025","unstructured":"Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol Dial Transplant. 2025;40(6):1175\u201386. https:\/\/doi.org\/10.1093\/ndt\/gfae263.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2229_CR42","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41440-024-01970-7","volume":"48","author":"Y Yoshida","year":"2025","unstructured":"Yoshida Y, Shibata H. Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism. Hypertens Res. 2025;48(2):854\u201361. https:\/\/doi.org\/10.1038\/s41440-024-01970-7.","journal-title":"Hypertens Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02229-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:21Z","timestamp":1761715881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02229-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02229-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to update the equally contributed.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Alma Mater Studiorum - Universit\u00e0 di Bologna within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Conceptualization: AFGC and FF. Data curation: AFGC, GT, AA, PP, GN, FP, CB, and FF. Investigation: AFGC, GT, AA, PP, and FF. Methodology: AFGC, GT, AA, PP, GN, FP, CB, and FF. Project administration: AFGC, GT, and FF. Supervision: AFGC and FF. Visualization: AA, FP, and FF. Writing: AFGC, GT, AA, PP, and FF. Reviewing and editing: GN, FP, and CB","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Claudio Borghi has received personal fees from Servier Pharma, EGIS Pharma, the Menarini Group, and Mineralys Therapeutics. Arrigo FG Cicero, Giuliano Tocci, Ashot Avagimyan, Peter Penson, Giulia Nardoianni, Francesco Perone, and Federica Fogacci have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}